论文部分内容阅读
目的探讨吡柔比星灌注化疗对经尿道电切术(TURBt)治疗的浅表性膀胱肿瘤患者的影响。方法选取2012年4月—2013年12月成都市第七人民医院收治的浅表性膀胱癌患者78例,根据术后化疗方案不同将患者分为吡柔比星组41例和丝裂霉素组37例。观察两组二次电切情况以及术后复发率。结果吡柔比星组患者进行二次电切17例(41.5%),其中二次电切肿瘤残留3例(17.6%),分级提高2例(11.8%);丝裂霉素组患者进行二次电切19例(51.4%),其中二次电切肿瘤残留4例(21.1%),分级提高4例(21.1%)。两组患者二次电切手术率、二次电切肿瘤残留率、分级提高发生率比较,差异无统计学意义(P>0.05)。两组毒副作用发生率比较,差异无统计学意义(P>0.05)。随访1、2年内两组复发率比较,差异无统计学意义(P>0.05);随访1、2年内吡柔比星组复发时间均长于丝裂霉素组,差异有统计学意义(P<0.05)。结论吡柔比星灌注化疗可提高TURBt治疗浅表性膀胱癌的疗效,复发率低。
Objective To investigate the effect of pirarubicin perfusion chemotherapy on patients with superficial bladder tumor treated with transurethral resection of the urethra (TURBt). Methods Seventy-eight patients with superficial bladder cancer admitted to Chengdu Seventh People’s Hospital from April 2012 to December 2013 were selected. According to the different postoperative chemotherapy regimens, the patients were divided into 41 cases of pirarubicin and mitomycin Group of 37 cases. Observed two groups of secondary resection and postoperative recurrence rate. Results In the pirarubicin group, 17 cases (41.5%) were subjected to secondary resection, of which 3 cases (17.6%) were cured by secondary resection and 2 cases (11.8%) were graded. The patients in mitomycin group There were 19 cases (51.4%) with subtotal resection, including 4 cases (21.1%) with secondary resection tumor and 4 cases (21.1%) with grading. There was no significant difference between the two groups in the rate of secondary resection, the rate of residual resection of secondary resection and the grade of grading (P> 0.05). There was no significant difference in the incidence of side effects between the two groups (P> 0.05). There was no significant difference in the recurrence rates between the two groups during the follow-up of 1 and 2 years (P> 0.05). The recurrence time in the pirarubicin group was longer than that in the mitomycin group at 1 and 2 years follow-up (P < 0.05). Conclusion Pirarubicin perfusion chemotherapy can improve the efficacy of TURBt in the treatment of superficial bladder cancer with low recurrence rate.